Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Open Access
- 9 September 2024
- journal article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Abstract
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.Keywords
This publication has 17 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysisOpen Heart, 2023
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunctionNature Reviews Nephrology, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyEP Europace, 2015
- Are Hospitalized or Ambulatory Patients with Heart Failure Treated in Accordance with European Society of Cardiology Guidelines? Evidence from 12 440 Patients of the ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure, 2013
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachChest, 2010